The Relationship Between HLA Tissue Compatibility and Biliary Complications in Patients With Liver Transplantation

Liver Transplant; Complications Clinical Trial

Official title:

The Relationship Between HLA Tissue Compatibility and Biliary Complications in Patients With Liver Transplantation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04885582
• Other study ID #: 2017/133
• Status: Completed
• Start date: May 10, 2017
• Est. completion date: May 20, 2020

Study information

• Verified date: May 2021
• Source: Inonu University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Liver transplantation has become the accepted treatment option for advanced liver failure in recent years. In addition to the increase in the number of centers performing transplant and the decrease in complication rates depending on the experience gained, the most common biliary complications did not improve at the desired level. For this reason, studies in this field are frequent today. The structural complexities of HLA antigens have been the subject of investigation in recent years. With the development of DNA and RNA amplification methods; It is increasingly difficult for physicians to keep up with the increasing burden of knowledge regarding the genetic aspects of these antigens. Concrete benefits of this gene complex, which has been investigated in various fields and preserves its mystery, have not been determined in liver transplant patients. However, there are publications showing its connection with the bile epithelium in liver transplantation and its relationship with the disappearing bile duct syndrome. In this study, our aim is to explain whether the bile duct complications, which appear like a continuous wall and can lead to frightening pictures, are related to HLA tissue compatibility.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: May 20, 2020
• Est. primary completion date: May 10, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 1 Year to 70 Years

Eligibility

Inclusion Criteria:

• patients with liver transplantation and tested for HLA antigen (recipient - donor)

Exclusion Criteria:

• patients who died early Patients whose HLA antigen is not checked

Related Conditions & MeSH terms

• Liver Transplant; Complications

Intervention

Other:
• HLA antigen results
HLA-A, HLA-B, HLA-DR tissue matching results in both groups will be compared.

Locations

Country	Name	City	State
Turkey	Health science University - Kayseri State Hospital	Kocasinan	Kayseri

Sponsors (1)

Lead Sponsor	Collaborator
Inonu University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bliary complications	Biliary fistüla, biliary stenosis	2 years